Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Chardan Capital Markets Starts Tourmaline Bio (TRML) at Buy
-
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
-
Japan Go IPO Summit Announces Roster of Expert Speakers for Event June 5th in Tokyo
-
/C O R R E C T I O N -- Marcum Asia CPAs LLP/
-
Chardan Capital Markets Starts Korro Bio Inc. (KRRO) at Buy
-
Kodiak to Go Public Via Business Combination With Ares Acquisition Corporation II (AACT)
-
Kodiak, a Leading Provider of AI-Powered Autonomous Vehicle Technology, to Go Public Via Business Combination With Ares Acquisition Corporation II
-
Form X-17A-5 CHARDAN CAPITAL MARKETS For: Dec 31
-
Centri Announces Sponsors for Capital Conference at Nasdaq on April 22
-
Chardan Capital Markets Starts Palvella Therapeutics (PVLA) at Buy
-
Chardan Capital Markets Assumes uniQure BV (QURE) at Buy, PT $38
-
Chardan Capital Markets Reiterates Neutral Rating on Allurion Technologies (ALUR)
-
Zura Bio Ltd. (ZURA) PT Lowered to $10 at Chardan Capital Markets
-
Japan Go IPO Summit Provides Roadmap for Japanese Companies Seeking to List on U.S. Exchanges
-
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq
-
Prime Medicine (PRME) PT Lowered to $16 at Chardan Capital Markets
-
Vincerx Pharma (VINC) Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
-
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
-
Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN)
-
Chardan Capital Markets Upgrades CervoMed (CRVO) to Buy
-
Passage Bio Inc. (PASG) PT Lowered to $6 at Chardan Capital Markets
-
Instinct Brothers to Go Public via Merger with Relativity Acquisition Corp (BIOT)
-
Instinct Brothers Co., Ltd, a Japanese Vertically Integrated Regenerative Medicine & Stem Cell Technology Company, to Go Public via Merger with Relativity Acquisition Corp.
-
Instinct Brothers Co., Ltd, a Japanese Vertically Integrated Regenerative Medicine & Stem Cell Technology Company, to Go Public via Merger with Relativity Acquisition Corp.
-
Dragonfly Energy Holdings (DFLI) Announces Corporate Debt Restructuring and Capital Raise
-
Dragonfly Energy Announces Corporate Debt Restructuring and Capital Raise
-
Urgently Announces Capital Structure Improvements and Secures up to $20 Million in New Financing
-
Senti Biosciences (SNTI) Strengthens Leadership Team with Strategic Hires
-
Senti Bio Strengthens Leadership Team with Strategic Hires
-
Eyenovia Inc (EYEN) Announces Debt Restructuring Including Amendment to Senior Secured Debt
-
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives
-
Form SEC STAFF ACTION CHARDAN NEXTECH ACQUISIT
-
Centri Capital Conference at Nasdaq Approaches
-
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Chardan Capital Markets Downgrades Cargo Therapeutics (CRGX) to Neutral
-
Chardan Capital Markets Starts Unity Biotechnology Inc (UBX) at Buy
-
uniQure (QURE) Prices 4.41M Share Offering at $17/sh
-
uniQure Announces Pricing of its Public Offering
-
Eyenovia (EYEN) Engages Chardan as Advisor for Review of Strategic Alternatives
-
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives
-
Chardan Capital Markets Downgrades Editas Medicine (EDIT) to Neutral
-
Chardan Capital Markets Downgrades CervoMed (CRVO) to Neutral
-
Sonnet BioTherapeutics (SONN) Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
-
Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
-
Eyenovia Inc (EYEN) Prices 20.09M Share Offering at $0.0969
-
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
-
Ace Green Recycling, a Global Leader in Battery Recycling Technology, to Become a Public Company
-
/C O R R E C T I O N -- ACE Green Recycling/
-
Senti Biosciences, Inc. (SNTI) PT Raised to $12 at Chardan Capital Markets
-
Chardan Capital Markets Downgrades Outlook Therapeutics Incs. (OTLK) to Neutral

